1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Bivalent Subtype C gp120: new trials by email Literature Review of Bivalent Subtype C gp120 trials Research Report on Bivalent Subtype C gp120
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59, Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 132 | 2017-06-19 | 2026-07-24 |
HIV Infections (1)
National Institute of Allergy and Infectious Diseases (NIAID) (1)
Mozambique (1) · South Africa (1) · Zimbabwe (1)
Kathy Mngadi (1) · Paul Goepfert (1)